The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Candida albicans is responsible for most fungal infections in humans. Fluconazole is well established as a first-line management option for the treatment and prophylaxis of localized and systemic C. albicans infections. Fluconazole exhibits predictable pharmacokinetics and is effective, well tolerated and suitable for use in most patients with C. albicans infections, including children, the elderly and those with impaired immunity. Prophylactic administration of fluconazole can help to prevent fungal infections in patients receiving cytotoxic cancer therapy. The increasing use of fluconazole for the long-term prophylaxis and treatment of recurrent oral candidosis in AIDS patients has led to the emergence of C. albicans infections that are not responsive to conventional doses. Second-line therapy with a wider spectrum antifungal, such as itraconazole, should be sought if treatment with fluconazole fails. A solution formulation of itraconazole has recently been introduced to overcome the poor and variable absorption of its original capsule formulation. Efficacy and tolerability studies in HIV-positive or immunocompromised patients with C. albicans infections have shown that, although itraconazole solution is as effective as fluconazole, it is less well tolerated as first-line therapy. Itraconazole solution can be effective in AIDS patients with C. albicans infections that are non-responsive to fluconazole. No efficacy or tolerability data are available on the use of itraconazole solution in children or the elderly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 1×
“Recent papers have discussed the technical advances and potential clinical applications of the susceptibility method and the development of interpretive breakpoints aimed to reduce this variability.(71,72) Although such sensitivity testing can be a useful guide to clinical outcome, caution should be exercised, as ther…”
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Marr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145
Pharmacokinetics of fluconazole in pediatric patients
Brammer, K. W., & Coates, P. E. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974613 · Cited by 139
Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life
Saxén, H., Hoppu, K., & Pohjavuori, M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.147 · Cited by 127 · cited 1×
“Neonates (aged 4 weeks) excrete fluconazole slowly, and less frequent dosing is therefore desirable.(19,20) The pharmacokinetics of fluconazole in the elderly are similar to those in non-elderly adults.”
BackgroundCandida Prosthetic Valve Endocarditis: Prospective Study of Six Cases and Review of the Literature
Nguyen, M. H., Nguyen, M. L., Vu, V. L., McMahon, D., Keys, T. F., & Amidi, M. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.262 · Cited by 109
Itraconazole: pharmacology, clinical experience and future development
De Beule, K. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00043-7 · Cited by 96
Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S. G., Craib, K., & Clarke, A. M. (1996) · AIDS · doi:10.1097/00002030-199610000-00009 · Cited by 88 · cited 1×
“Among 36 HIVpositive patients who were non-responsive to fluconazole for oropharyngeal candidosis, 65% responded to itraconazole solution.(79) Itraconazole solution is recommended for the treatment of oral and oesophageal candidosis in AIDS patients who are non-responsive to fluconazole, but a”
Background
Cited by
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.027 · Cited by 527
Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae
Brennan, M. (2002) · FEMS Immunology and Medical Microbiology · doi:10.1016/s0928-8244(02)00374-7 · Cited by 357
Cinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
Hirasawa, M. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh046 · Cited by 260
Shih, P.-Y., Liao, Y.-T., Tseng, Y.-K., Deng, F.-S., & Lin, C.-H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00602 · Cited by 156
“…of human fungal pathogens has dramatically increased worldwide (Bertagnolio et al., 2004; Wisplinghoff et al., 2004; Yang et al., 2010), leading to a reduction in the efficacy of treatments for fungal infection (Martin, 1999; Angiolella et al., 2008; Chang et al., 2013; Ford et al., 2015).”
Background
Metadata
- Authors
- Martin, M. V.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-10
- Volume
- 44
- Issue
- 4
- Pages
- 429-437
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2164270244
- Cited by
- 150
- References
- 9
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.